Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

John Schiller

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Living Beings

Disorders

Chemicals & Drugs

Anatomy

Procedures

Physiology

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Schiller John T; Lowy Douglas R
Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials.
Jagu Subhashini; Karanam Balasubramanyam; Gambhira Ratish; Chivukula Sudha V; Chaganti Revathi J; Lowy Douglas R; Schiller John T; Roden Richard B S
Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.
Johnson Katherine M; Kines Rhonda C; Roberts Jeffrey N; Lowy Douglas R; Schiller John T; Day Patricia M
Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of John Schiller (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Schiller John T; Lowy Douglas R
Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials.
The Journal of infectious diseases 2009;200(2):166-71.
2009: Jagu Subhashini; Karanam Balasubramanyam; Gambhira Ratish; Chivukula Sudha V; Chaganti Revathi J; Lowy Douglas R; Schiller John T; Roden Richard B S
Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.
Journal of the National Cancer Institute 2009;101(11):782-92.
2009: Johnson Katherine M; Kines Rhonda C; Roberts Jeffrey N; Lowy Douglas R; Schiller John T; Day Patricia M
Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus.
Journal of virology 2009;83(5):2067-74.
2008: Day Patricia M; Lowy Douglas R; Schiller John T
Heparan sulfate-independent cell binding and infection with furin-precleaved papillomavirus capsids.
Journal of virology 2008;82(24):12565-8.
2008: Lowy Douglas R; Solomon Diane; Hildesheim Allan; Schiller John T; Schiffman Mark
Human papillomavirus infection and the primary and secondary prevention of cervical cancer.
Cancer 2008;113(7 Suppl):1980-93.
2008: Schiller John T; Castellsagué Xavier; Villa Luisa L; Hildesheim Allan
An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results.
Vaccine 2008;26 Suppl 10():K53-61.
2008: Buck Christopher B; Cheng Naiqian; Thompson Cynthia D; Lowy Douglas R; Steven Alasdair C; Schiller John T; Trus Benes L
Arrangement of L2 within the papillomavirus capsid.
Journal of virology 2008;82(11):5190-7.
2008: Chackerian Bryce; Durfee Marisa R; Schiller John T
Virus-like display of a neo-self antigen reverses B cell anergy in a B cell receptor transgenic mouse model.
Journal of immunology (Baltimore, Md. : 1950) 2008;180(9):5816-25.
2008: Day Patricia M; Gambhira Ratish; Roden Richard B S; Lowy Douglas R; Schiller John T
Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies.
Journal of virology 2008;82(9):4638-46.
2008: Alphs Hannah H; Gambhira Ratish; Karanam Balasubramanyam; Roberts Jeffrey N; Jagu Subhashini; Schiller John T; Zeng Weiguang; Jackson David C; Roden Richard B S
Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2.
Proceedings of the National Academy of Sciences of the United States of America 2008;105(15):5850-5.
2008: Kemp Troy J; Hildesheim Allan; Falk Roni T; Schiller John T; Lowy Douglas R; Rodriguez Ana Cecilia; Pinto Ligia A
Evaluation of two types of sponges used to collect cervical secretions and assessment of antibody extraction protocols for recovery of neutralizing anti-human papillomavirus type 16 antibodies.
Clinical and vaccine immunology : CVI 2008;15(1):60-4.
2007: Revaz Véronique; Zurbriggen Rinaldo; Moser Christian; Schiller John T; Ponci Françoise; Bobst Martine; Nardelli-Haefliger Denise
Humoral and cellular immune responses to airway immunization of mice with human papillomavirus type 16 virus-like particles and mucosal adjuvants.
Antiviral research 2007;76(1):75-85.
2007: Hildesheim Allan; Herrero Rolando; Wacholder Sholom; Rodriguez Ana C; Solomon Diane; Bratti M Concepcion; Schiller John T; Gonzalez Paula; Dubin Gary; Porras Carolina; Jimenez Silvia E; Lowy Douglas R;
Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial.
JAMA : the journal of the American Medical Association 2007;298(7):743-53.
2007: García-Piñeres Alfonso; Hildesheim Allan; Dodd Lori; Kemp Troy J; Williams Marcus; Harro Clayton; Lowy Douglas R; Schiller John T; Pinto Ligia A
Cytokine and chemokine profiles following vaccination with human papillomavirus type 16 L1 Virus-like particles.
Clinical and vaccine immunology : CVI 2007;14(8):984-9.
2007: Day Patricia M; Thompson Cynthia D; Buck Christopher B; Pang Yuk-Ying S; Lowy Douglas R; Schiller John T
Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition.
Journal of virology 2007;81(16):8784-92.
2007: Roberts Jeffrey N; Buck Christopher B; Thompson Cynthia D; Kines Rhonda; Bernardo Marcelino; Choyke Peter L; Lowy Douglas R; Schiller John T
Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan.
Nature medicine 2007;13(7):857-61.
2006: Schiller John T; Lowy Douglas R
Prospects for cervical cancer prevention by human papillomavirus vaccination.
Cancer research 2006;66(21):10229-32.
2006: Pinto Ligia A; Viscidi Raphael; Harro Clayton D; Kemp Troy J; García-Piñeres Alfonso J; Trivett Matthew; Demuth Franklin; Lowy Douglas R; Schiller John T; Berzofsky Jay A; Hildesheim Allan
Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
Virology 2006;353(2):451-62.
2006: Schiller John T; Nardelli-Haefliger Denise
Chapter 17: Second generation HPV vaccines to prevent cervical cancer.
Vaccine 2006;24 Suppl 3():S3/147-53.
2006: Kamangar Farin; Qiao You-Lin; Schiller John T; Dawsey Sanford M; Fears Thomas; Sun Xui-Di; Abnet Christian C; Zhao Ping; Taylor Philip R; Mark Steven D
Human papillomavirus serology and the risk of esophageal and gastric cancers: results from a cohort in a high-risk region in China.
International journal of cancer. Journal international du cancer 2006;119(3):579-84.
2006: Buck Christopher B; Thompson Cynthia D; Roberts Jeffrey N; Müller Martin; Lowy Douglas R; Schiller John T
Carrageenan is a potent inhibitor of papillomavirus infection.
PLoS pathogens 2006;2(7):e69.
2006: Qian Jiahua; Dong Yujun; Pang Yuk-Ying S; Ibrahim Ramy; Berzofsky Jay A; Schiller John T; Khleif Samir N
Combined prophylactic and therapeutic cancer vaccine: enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice.
International journal of cancer. Journal international du cancer 2006;118(12):3022-9.
2006: Lowy Douglas R; Schiller John T
Prophylactic human papillomavirus vaccines.
The Journal of clinical investigation 2006;116(5):1167-73.
2006: Buck Christopher B; Day Patricia M; Thompson Cynthia D; Lubkowski Jacek; Lu Wuyuan; Lowy Douglas R; Schiller John T
Human alpha-defensins block papillomavirus infection.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(5):1516-21.
2006: Richards Rebecca M; Lowy Douglas R; Schiller John T; Day Patricia M
Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(5):1522-7.
2006: Kämper Nadine; Day Patricia M; Nowak Thorsten; Selinka Hans-Christoph; Florin Luise; Bolscher Jan; Hilbig Lydia; Schiller John T; Sapp Martin
A membrane-destabilizing peptide in capsid protein L2 is required for egress of papillomavirus genomes from endosomes.
Journal of virology 2006;80(2):759-68.
2005: Pastrana Diana V; Gambhira Ratish; Buck Christopher B; Pang Yuk-Ying S; Thompson Cynthia D; Culp Timothy D; Christensen Neil D; Lowy Douglas R; Schiller John T; Roden Richard B S
Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2.
Virology 2005;337(2):365-72.
2005: Nardelli-Haefliger Denise; Lurati Floriana; Wirthner Daniel; Spertini François; Schiller John T; Lowy Douglas R; Ponci Françoise; De Grandi Pierre
Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine.
Vaccine 2005;23(28):3634-41.
2005: Pinto Ligia A; Castle Philip E; Roden Richard B; Harro Clayton D; Lowy Douglas R; Schiller John T; Wallace Dora; Williams Marcus; Kopp William; Frazer Ian H; Berzofsky Jay A; Hildesheim Allan
HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood.
Vaccine 2005;23(27):3555-64.
2005: Lenz Petra; Lowy Douglas R; Schiller John T
Papillomavirus virus-like particles induce cytokines characteristic of innate immune responses in plasmacytoid dendritic cells.
European journal of immunology 2005;35(5):1548-56.
2005: Buck Christopher B; Thompson Cynthia D; Pang Yuk-Ying S; Lowy Douglas R; Schiller John T
Maturation of papillomavirus capsids.
Journal of virology 2005;79(5):2839-46.
2005: Buck Christopher B; Pastrana Diana V; Lowy Douglas R; Schiller John T
Generation of HPV pseudovirions using transfection and their use in neutralization assays.
Methods in molecular medicine 2005;119():445-62.
2004: Day Patricia M; Baker Carl C; Lowy Douglas R; Schiller John T
Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expression.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(39):14252-7.
2004: Pastrana Diana V; Buck Christopher B; Pang Yuk-Ying S; Thompson Cynthia D; Castle Philip E; FitzGerald Peter C; Krüger Kjaer Susanne; Lowy Douglas R; Schiller John T
Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.
Virology 2004;321(2):205-16.
2004: Chackerian Bryce; Briglio Lindsey; Albert Paul S; Lowy Douglas R; Schiller John T
Induction of autoantibodies to CCR5 in macaques and subsequent effects upon challenge with an R5-tropic simian/human immunodeficiency virus.
Journal of virology 2004;78(8):4037-47.
2004: Schiller John T; Davies Philip
Delivering on the promise: HPV vaccines and cervical cancer.
Nature reviews. Microbiology 2004;2(4):343-7.
2004: Buck Christopher B; Pastrana Diana V; Lowy Douglas R; Schiller John T
Efficient intracellular assembly of papillomaviral vectors.
Journal of virology 2004;78(2):751-7.
2003: Nardelli-Haefliger Denise; Wirthner Daniel; Schiller John T; Lowy Douglas R; Hildesheim Allan; Ponci Françoise; De Grandi Pierre
Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles.
Journal of the National Cancer Institute 2003;95(15):1128-37.
2003: Pinto Ligia A; Edwards Jessica; Castle Philip E; Harro Clayton D; Lowy Douglas R; Schiller John T; Wallace Dora; Kopp William; Adelsberger Joseph W; Baseler Michael W; Berzofsky Jay A; Hildesheim Allan
Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
The Journal of infectious diseases 2003;188(2):327-38.
2003: Da Silva Diane M; Schiller John T; Kast W Martin
Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines.
Vaccine 2003;21(23):3219-27.
2003: Lenz Petra; Thompson Cynthia D; Day Patricia M; Bacot Silvia M; Lowy Douglas R; Schiller John T
Interaction of papillomavirus virus-like particles with human myeloid antigen-presenting cells.
Clinical immunology (Orlando, Fla.) 2003;106(3):231-7.
2003: Day Patricia M; Lowy Douglas R; Schiller John T
Papillomaviruses infect cells via a clathrin-dependent pathway.
Virology 2003;307(1):1-11.
2002: Wong May; Pagano Joseph S; Schiller John T; Tevethia Satvir S; Raab-Traub Nancy; Gruber Jack
New associations of human papillomavirus, Simian virus 40, and Epstein-Barr virus with human cancer.
Journal of the National Cancer Institute 2002;94(24):1832-6.
2002: Chackerian Bryce; Lenz Petra; Lowy Douglas R; Schiller John T
Determinants of autoantibody induction by conjugated papillomavirus virus-like particles.
Journal of immunology (Baltimore, Md. : 1950) 2002;169(11):6120-6.
2001: Da Silva D M; Pastrana D V; Schiller J T; Kast W M
Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines.
Virology 2001;290(2):350-60.
2001: Roden R B; Day P M; Bronzo B K; Yutzy W H; Yang Y; Lowy D R; Schiller J T
Positively charged termini of the L2 minor capsid protein are necessary for papillomavirus infection.
Journal of virology 2001;75(21):10493-7.
2001: Chackerian B; Lowy D R; Schiller J T
Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies.
The Journal of clinical investigation 2001;108(3):415-23.
2001: Schiller J T; Lowy D R
Papillomavirus-like particle based vaccines: cervical cancer and beyond.
Expert opinion on biological therapy 2001;1(4):571-81.
2001: Lenz P; Day P M; Pang Y Y; Frye S A; Jensen P N; Lowy D R; Schiller J T
Papillomavirus-like particles induce acute activation of dendritic cells.
Journal of immunology (Baltimore, Md. : 1950) 2001;166(9):5346-55.
2001: Da Silva D M; Velders M P; Nieland J D; Schiller J T; Nickoloff B J; Kast W M
Physical interaction of human papillomavirus virus-like particles with immune cells.
International immunology 2001;13(5):633-41.
2001: Okun M M; Day P M; Greenstone H L; Booy F P; Lowy D R; Schiller J T; Roden R B
L1 interaction domains of papillomavirus l2 necessary for viral genome encapsidation.
Journal of virology 2001;75(9):4332-42.
2001: Kjaer S K; Chackerian B; van den Brule A J; Svare E I; Paull G; Walbomers J M; Schiller J T; Bock J E; Sherman M E; Lowy D R; Meijer C L
High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse).
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2001;10(2):101-6.
2001: Harro C D; Pang Y Y; Roden R B; Hildesheim A; Wang Z; Reynolds M J; Mast T C; Robinson R; Murphy B R; Karron R A; Dillner J; Schiller J T; Lowy D R
Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine.
Journal of the National Cancer Institute 2001;93(4):284-92.
2001: Pastrana D V; Vass W C; Lowy D R; Schiller J T
NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16.
Virology 2001;279(1):361-9.
2001: Revaz V; Benyacoub J; Kast W M; Schiller J T; De Grandi P; Nardelli-Haefliger D
Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice.
Virology 2001;279(1):354-60.
2001: Schiller J T; Lowy D R
Papillomavirus-like particle vaccines.
Journal of the National Cancer Institute. Monographs 2001;(28):50-4.
2000: Roden R B; Yutzy W H; Fallon R; Inglis S; Lowy D R; Schiller J T
Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes.
Virology 2000;270(2):254-7.
1999: Wideroff L; Schiffman M; Haderer P; Armstrong A; Greer C E; Manos M M; Burk R D; Scott D R; Sherman M E; Schiller J T; Hoover R N; Tarone R E; Kirnbauer R
Seroreactivity to human papillomavirus types 16, 18, 31, and 45 virus-like particles in a case-control study of cervical squamous intraepithelial lesions.
The Journal of infectious diseases 1999;180(5):1424-8.
1999: Schiller J T
Papillomavirus-like particle vaccines for cervical cancer.
Molecular medicine today 1999;5(5):209-15.
1999: Nieland J D; Da Silva D M; Velders M P; de Visser K E; Schiller J T; Müller M; Kast W M
Chimeric papillomavirus virus-like particles induce a murine self-antigen-specific protective and therapeutic antitumor immune response.
Journal of cellular biochemistry 1999;73(2):145-52.
1999: Rudolf M P; Nieland J D; DaSilva D M; Velders M P; Müller M; Greenstone H L; Schiller J T; Kast W M
Induction of HPV16 capsid protein-specific human T cell responses by virus-like particles.
Biological chemistry 1999;380(3):335-40.
1999: Chackerian B; Lowy D R; Schiller J T
Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(5):2373-8.
1999: Da Silva D M; Velders M P; Rudolf M P; Schiller J T; Kast W M
Papillomavirus virus-like particles as anticancer vaccines.
Current opinion in molecular therapeutics 1999;1(1):82-8.
1999: Lowy D R; Schiller J T
Papillomaviruses: prophylactic vaccine prospects.
Biochimica et biophysica acta 1999;1423(1):M1-8.
1998: De Bruijn M L; Greenstone H L; Vermeulen H; Melief C J; Lowy D R; Schiller J T; Kast W M
L1-specific protection from tumor challenge elicited by HPV16 virus-like particles.
Virology 1998;250(2):371-6.
1998: Booy F P; Roden R B; Greenstone H L; Schiller J T; Trus B L
Two antibodies that neutralize papillomavirus by different mechanisms show distinct binding patterns at 13 A resolution.
Journal of molecular biology 1998;281(1):95-106.
1998: Greenstone H L; Nieland J D; de Visser K E; De Bruijn M L; Kirnbauer R; Roden R B; Lowy D R; Kast W M; Schiller J T
Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model.
Proceedings of the National Academy of Sciences of the United States of America 1998;95(4):1800-5.
1998: Day P M; Roden R B; Lowy D R; Schiller J T
The papillomavirus minor capsid protein, L2, induces localization of the major capsid protein, L1, and the viral transcription/replication protein, E2, to PML oncogenic domains.
Journal of virology 1998;72(1):142-50.
1998: Lowy D R; Schiller J T
Papillomaviruses and cervical cancer: pathogenesis and vaccine development.
Journal of the National Cancer Institute. Monographs 1998;(23):27-30.
1997: Roden R B; Lowy D R; Schiller J T
Papillomavirus is resistant to desiccation.
The Journal of infectious diseases 1997;176(4):1076-9.
1997: Svare E I; Kjaer S K; Nonnenmacher B; Worm A M; Moi H; Christensen R B; van den Brule A J; Walboomers J M; Meijer C J; Hubbert N L; Lowy D R; Schiller J T
Seroreactivity to human papillomavirus type 16 virus-like particles is lower in high-risk men than in high-risk women.
The Journal of infectious diseases 1997;176(4):876-83.
1997: Nardelli-Haefliger D; Roden R B; Benyacoub J; Sahli R; Kraehenbuhl J P; Schiller J T; Lachat P; Potts A; De Grandi P
Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice.
Infection and immunity 1997;65(8):3328-36.
1997: Roden R B; Armstrong A; Haderer P; Christensen N D; Hubbert N L; Lowy D R; Schiller J T; Kirnbauer R
Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope.
Journal of virology 1997;71(8):6247-52.
1997: Strickler H D; Hildesheim A; Viscidi R P; Shah K V; Goebel B; Drummond J; Waters D; Sun Y; Hubbert N L; Wacholder S; Brinton L A; Han C L; Nasca P C; McClimens R; Turk K; Devairakkam V; Leitman S; Martin C; Schiller J T
Interlaboratory agreement among results of human papillomavirus type 16 enzyme-linked immunosorbent assays.
Journal of clinical microbiology 1997;35(7):1751-6.
1997: Trus B L; Roden R B; Greenstone H L; Vrhel M; Schiller J T; Booy F P
Novel structural features of bovine papillomavirus capsid revealed by a three-dimensional reconstruction to 9 A resolution.
Nature structural biology 1997;4(5):413-20.
1997: Strickler H D; Schiffman M H; Eklund C; Glass A G; Scott D R; Sherman M E; Wacholder S; Kurman R J; Manos M M; Schiller J T; Dillner J
Evidence for at least two distinct groups of humoral immune reactions to papillomavirus antigens in women with squamous intraepithelial lesions.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 1997;6(3):183-8.
1996: Schiller J T; Lowy D R
Papillomavirus-like particles and HPV vaccine development.
Seminars in cancer biology 1996;7(6):373-82.
1996: Nonnenmacher B; Kruger Kjaer S; Svare E I; Scott J D; Hubbert N L; van den Brule A J; Kirnbauer R; Walboomers J M; Lowy D R; Schiller J T
Seroreactivity to HPV16 virus-like particles as a marker for cervical cancer risk in high-risk populations.
International journal of cancer. Journal international du cancer 1996;68(6):704-9.
1996: Wang Z; Hansson B G; Forslund O; Dillner L; Sapp M; Schiller J T; Bjerre B; Dillner J
Cervical mucus antibodies against human papillomavirus type 16, 18, and 33 capsids in relation to presence of viral DNA.
Journal of clinical microbiology 1996;34(12):3056-62.
1996: Steller M A; Zou Z; Schiller J T; Baserga R
Transformation by human papillomavirus 16 E6 and E7: role of the insulin-like growth factor 1 receptor.
Cancer research 1996;56(21):5087-91.
1996: Han C; Qiao G; Hubbert N L; Li L; Sun C; Wang Y; Yan M; Xu D; Li Y; Lowy D R; Schiller J T
Serologic association between human papillomavirus type 16 infection and esophageal cancer in Shaanxi Province, China.
Journal of the National Cancer Institute 1996;88(20):1467-71.
1996: Roden R B; Greenstone H L; Kirnbauer R; Booy F P; Jessie J; Lowy D R; Schiller J T
In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype.
Journal of virology 1996;70(9):5875-83.
1996: Dillner J; Kallings I; Brihmer C; Sikström B; Koskela P; Lehtinen M; Schiller J T; Sapp M; Mårdh P A
Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior.
The Journal of infectious diseases 1996;173(6):1394-8.
1996: Roden R B; Hubbert N L; Kirnbauer R; Christensen N D; Lowy D R; Schiller J T
Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition.
Journal of virology 1996;70(5):3298-301.
1996: Kirnbauer R; Chandrachud L M; O'Neil B W; Wagner E R; Grindlay G J; Armstrong A; McGarvie G M; Schiller J T; Lowy D R; Campo M S
Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization.
Virology 1996;219(1):37-44.
1996: Steller M A; Schiller J T
Human papillomavirus immunology and vaccine prospects.
Journal of the National Cancer Institute. Monographs 1996;(21):145-8.
1996: Lowy D R; Schiller J T
Human papillomavirus biology.
Journal of the National Cancer Institute. Monographs 1996;(21):141-3.
1996: Schiller J T; Okun M M
Papillomavirus vaccines: current status and future prospects.
Advances in dermatology 1996;11():355-80; discussion 381.
1995: Cheng G; Icenogle J P; Kirnbauer R; Hubbert N L; St Louis M E; Han C; Svare E I; Kjaer S K; Lowy D R; Schiller J T
Divergent human papillomavirus type 16 variants are serologically cross-reactive.
The Journal of infectious diseases 1995;172(6):1584-7.
1995: Roden R B; Hubbert N L; Kirnbauer R; Breitburd F; Lowy D R; Schiller J T
Papillomavirus L1 capsids agglutinate mouse erythrocytes through a proteinaceous receptor.
Journal of virology 1995;69(8):5147-51.
1995: Nonnenmacher B; Hubbert N L; Kirnbauer R; Shah K V; Muñoz N; Bosch F X; de Sanjosé S; Viscidi R; Lowy D R; Schiller J T
Serologic response to human papillomavirus type 16 (HPV-16) virus-like particles in HPV-16 DNA-positive invasive cervical cancer and cervical intraepithelial neoplasia grade III patients and controls from Colombia and Spain.
The Journal of infectious diseases 1995;172(1):19-24.
1995: Breitburd F; Kirnbauer R; Hubbert N L; Nonnenmacher B; Trin-Dinh-Desmarquet C; Orth G; Schiller J T; Lowy D R
Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection.
Journal of virology 1995;69(6):3959-63.
1995: Wikström A; van Doornum G J; Quint W G; Schiller J T; Dillner J
Identification of human papillomavirus seroconversions.
The Journal of general virology 1995;76 ( Pt 3)():529-39.
1995: Heino P; Eklund C; Fredriksson-Shanazarian V; Goldman S; Schiller J T; Dillner J
Association of serum immunoglobulin G antibodies against human papillomavirus type 16 capsids with anal epidermoid carcinoma.
Journal of the National Cancer Institute 1995;87(6):437-40.
1995: Dillner J; Wiklund F; Lenner P; Eklund C; Frederiksson-Shanazarian V; Schiller J T; Hibma M; Hallmans G; Stendahl U
Antibodies against linear and conformational epitopes of human papillomavirus type 16 that independently associate with incident cervical cancer.
International journal of cancer. Journal international du cancer 1995;60(3):377-82.
1994: Melillo R M; Helin K; Lowy D R; Schiller J T
Positive and negative regulation of cell proliferation by E2F-1: influence of protein level and human papillomavirus oncoproteins.
Molecular and cellular biology 1994;14(12):8241-9.
1994: Roden R B; Kirnbauer R; Jenson A B; Lowy D R; Schiller J T
Interaction of papillomaviruses with the cell surface.
Journal of virology 1994;68(11):7260-6.
1994: Roden R B; Weissinger E M; Henderson D W; Booy F; Kirnbauer R; Mushinski J F; Lowy D R; Schiller J T
Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins.
Journal of virology 1994;68(11):7570-4.
1994: Kirnbauer R; Hubbert N L; Wheeler C M; Becker T M; Lowy D R; Schiller J T
A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16.
Journal of the National Cancer Institute 1994;86(7):494-9.
1994: Lowy D R; Kirnbauer R; Schiller J T
Genital human papillomavirus infection.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(7):2436-40.
1993: Kirnbauer R; Taub J; Greenstone H; Roden R; Dürst M; Gissmann L; Lowy D R; Schiller J T
Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles.
Journal of virology 1993;67(12):6929-36.
1993: Cohen B D; Lowy D R; Schiller J T
The conserved C-terminal domain of the bovine papillomavirus E5 oncoprotein can associate with an alpha-adaptin-like molecule: a possible link between growth factor receptors and viral transformation.
Molecular and cellular biology 1993;13(10):6462-8.
1993: Cohen B D; Goldstein D J; Rutledge L; Vass W C; Lowy D R; Schlegel R; Schiller J T
Transformation-specific interaction of the bovine papillomavirus E5 oncoprotein with the platelet-derived growth factor receptor transmembrane domain and the epidermal growth factor receptor cytoplasmic domain.
Journal of virology 1993;67(9):5303-11.
1993: Lowy D R; Sedman S A; Cohen B D; Schiller J T
Human papillomaviruses and cancer.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1993;128():351-2.
1992: Kirnbauer R; Booy F; Cheng N; Lowy D R; Schiller J T
Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic.
Proceedings of the National Academy of Sciences of the United States of America 1992;89(24):12180-4.
1992: Hubbert N L; Sedman S A; Schiller J T
Human papillomavirus type 16 E6 increases the degradation rate of p53 in human keratinocytes.
Journal of virology 1992;66(10):6237-41.
1992: Sedman S A; Hubbert N L; Vass W C; Lowy D R; Schiller J T
Mutant p53 can substitute for human papillomavirus type 16 E6 in immortalization of human keratinocytes but does not have E6-associated trans-activation or transforming activity.
Journal of virology 1992;66(7):4201-8.
1991: Sedman S A; Barbosa M S; Vass W C; Hubbert N L; Haas J A; Lowy D R; Schiller J T
The full-length E6 protein of human papillomavirus type 16 has transforming and trans-activating activities and cooperates with E7 to immortalize keratinocytes in culture.
Journal of virology 1991;65(9):4860-6.
1991: Barbosa M S; Vass W C; Lowy D R; Schiller J T
In vitro biological activities of the E6 and E7 genes vary among human papillomaviruses of different oncogenic potential.
Journal of virology 1991;65(1):292-8.
1990: Barbosa M S; Edmonds C; Fisher C; Schiller J T; Lowy D R; Vousden K H
The region of the HPV E7 oncoprotein homologous to adenovirus E1a and Sv40 large T antigen contains separate domains for Rb binding and casein kinase II phosphorylation.
The EMBO journal 1990;9(1):153-60.
1989: Hawley-Nelson P; Vousden K H; Hubbert N L; Lowy D R; Schiller J T
HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes.
The EMBO journal 1989;8(12):3905-10.
1989: Martin P; Vass W C; Schiller J T; Lowy D R; Velu T J
The bovine papillomavirus E5 transforming protein can stimulate the transforming activity of EGF and CSF-1 receptors.
Cell 1989;59(1):21-32.
1989: Lambert P F; Hubbert N L; Howley P M; Schiller J T
Genetic assignment of multiple E2 gene products in bovine papillomavirus-transformed cells.
Journal of virology 1989;63(7):3151-4.
1989: Cerni C; Binétruy B; Schiller J T; Lowy D R; Meneguzzi G; Cuzin F
Successive steps in the process of immortalization identified by transfer of separate bovine papillomavirus genes into rat fibroblasts.
Proceedings of the National Academy of Sciences of the United States of America 1989;86(9):3266-70.
1989: Vousden K H; Androphy E J; Schiller J T; Lowy D R
Mutational analysis of bovine papillomavirus E6 gene.
Journal of virology 1989;63(5):2340-2.
1989: Schiller J T; Kleiner E; Androphy E J; Lowy D R; Pfister H
Identification of bovine papillomavirus E1 mutants with increased transforming and transcriptional activity.
Journal of virology 1989;63(4):1775-82.
1989: Barbosa M S; Lowy D R; Schiller J T
Papillomavirus polypeptides E6 and E7 are zinc-binding proteins.
Journal of virology 1989;63(3):1404-7.
1988: Hubbert N L; Schiller J T; Lowy D R; Androphy E J
Bovine papilloma virus-transformed cells contain multiple E2 proteins.
Proceedings of the National Academy of Sciences of the United States of America 1988;85(16):5864-8.
1988: Hawley-Nelson P; Androphy E J; Lowy D R; Schiller J T
The specific DNA recognition sequence of the bovine papillomavirus E2 protein is an E2-dependent enhancer.
The EMBO journal 1988;7(2):525-31.
1987: Androphy E J; Hubbert N L; Schiller J T; Lowy D R
Identification of the HPV-16 E6 protein from transformed mouse cells and human cervical carcinoma cell lines.
The EMBO journal 1987;6(4):989-92.
1985: Lowy D R; Schiller J T
Papillomaviruses.
Clinics in dermatology 1985;3(4):1-7.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

John Schiller

Research Profile (preview)

Living Beings

Disorders

Chemicals & Drugs

Anatomy

Procedures

Physiology

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of John Schiller (preview)

All Publications